231 related articles for article (PubMed ID: 9128950)
1. Predictive value of the flow cytometric PCNA assay (proliferating cell nuclear antigen) in head and neck tumors after accelerated-hyperfractionated radiochemotherapy.
Wenz F; Lohr F; Flentje M; Rudat V; Dietz A; Wannenmacher M
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):771-6. PubMed ID: 9128950
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08.
Fu KK; Hammond E; Pajak TF; Clery M; Doggett RL; Byhardt RW; McDonald S; Cooper JS
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):661-71. PubMed ID: 7913703
[TBL] [Abstract][Full Text] [Related]
3. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
4. [Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Dietz A; Rudat V; Nollert J; Flentje M; Maiei H; Wannenmacher M; Weidauer H
Laryngorhinootologie; 1996 Dec; 75(12):745-53. PubMed ID: 9081280
[TBL] [Abstract][Full Text] [Related]
5. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.
Huguenin P; Beer KT; Allal A; Rufibach K; Friedli C; Davis JB; Pestalozzi B; Schmid S; Thöni A; Ozsahin M; Bernier J; Töpfer M; Kann R; Meier UR; Thum P; Bieri S; Notter M; Lombriser N; Glanzmann C
J Clin Oncol; 2004 Dec; 22(23):4665-73. PubMed ID: 15534360
[TBL] [Abstract][Full Text] [Related]
6. Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report.
Arias F; Domínguez MA; Illarramendi JJ; Martínez E; Tejedor M; Domínguez S; Dueñas M; Villafranca E; Elcarte F; Miquéliz S
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):675-82. PubMed ID: 7558958
[TBL] [Abstract][Full Text] [Related]
7. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
8. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
[TBL] [Abstract][Full Text] [Related]
9. [Simultaneous radiochemotherapy with carboplatin in patients with inoperable advanced stage III and IV head and neck tumors].
Mücke R; Blynow M; Ziegler PG; Libera T; Kundt G; Dommerich S; Kramp B; Fietkau R
Strahlenther Onkol; 1999 May; 175(5):213-7. PubMed ID: 10356610
[TBL] [Abstract][Full Text] [Related]
10. A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck.
Jones AS; Roland NJ; Caslin AW; Cooke TG; Cooke LD; Forster G
J Laryngol Otol; 1994 Oct; 108(10):859-64. PubMed ID: 7989834
[TBL] [Abstract][Full Text] [Related]
11. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
[TBL] [Abstract][Full Text] [Related]
12. Ampullary carcinoma: prognostic significance of ploidy, cell-cycle analysis and proliferating cell nuclear antigen (PCNA).
Crucitti A; Masetti R; Breccia C; Coppola R; Magistrelli P; Nuzzo G; Maggiano N; Picciocchi A
Hepatogastroenterology; 1999; 46(26):1187-91. PubMed ID: 10370689
[TBL] [Abstract][Full Text] [Related]
13. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis.
Kawai T; Suzuki M; Kono S; Shinomiya N; Rokutanda M; Takagi K; Ogata T; Tamai S
Cancer; 1994 Nov; 74(9):2468-75. PubMed ID: 7923002
[TBL] [Abstract][Full Text] [Related]
14. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Haas ML; Conley BA; Egorin MJ; Levy S; Sivasailam S; Herman JM; Jacobs MC; Gray WC; Ord RA; Aisner JA; Van Echo DA
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):49-56. PubMed ID: 10758304
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience.
Zamboglou N; Schnabel T; Kolotas C; Achterrath W; Strehl H; Dalhäuser S; Vogt HG; Lenaz L; Schmitt G
Semin Oncol; 1994 Oct; 21(5 Suppl 12):45-53. PubMed ID: 7992066
[TBL] [Abstract][Full Text] [Related]
16. Potential doubling time in head and neck tumors treated by primary radiotherapy: preliminary evidence for a prognostic significance in local control.
Corvò R; Giaretti W; Sanguineti G; Geido E; Orecchia R; Barra S; Margarino G; Bacigalupo A; Vitale V
Int J Radiat Oncol Biol Phys; 1993 Dec; 27(5):1165-72. PubMed ID: 8262843
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric measurement of proliferating cell nuclear antigen (PCNA) in solid tumors.
Wenz F; Lohr F; Flentje M
Strahlenther Onkol; 1994 Apr; 170(4):235-42. PubMed ID: 8165522
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
[TBL] [Abstract][Full Text] [Related]
19. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
[TBL] [Abstract][Full Text] [Related]
20. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer.
Grabenbauer GG; Steininger H; Meyer M; Fietkau R; Brunner T; Heinkelmann P; Hornung J; Iro H; Spitzer W; Kirchner T; Sauer R; Distel L
Radiother Oncol; 1998 May; 47(2):175-83. PubMed ID: 9683366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
